Recombinant Mouse Arhgdia Protein, Myc/DDK-tagged
Cat.No. : | Arhgdia-1689M |
Product Overview : | Purified recombinant protein of mouse full-length Rho GDP dissociation inhibitor (GDI) alpha (Arhgdia), with C-terminal MYC/DDK tag, expressed in HEK293T cells. |
- Specification
- Gene Information
- Related Products
Description : | Controls Rho proteins homeostasis. Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Retains Rho proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool, regulating their stability and protecting them from degradation. Actively involved in the recycling and distribution of activated Rho GTPases in the cell, mediates extraction from membranes of both inactive and activated molecules due its exceptionally high affinity for prenylated forms. Through the modulation of Rho proteins, may play a role in cell motility regulation. In glioma cells, inhibits cell migration and invasion by mediating the signals of SEMA5A and PLXNB3 that lead to inactivation of RAC1. |
Source : | HEK293T |
Species : | Mouse |
Tag : | Myc/DDK |
Molecular Mass : | 23.4 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Stability : | Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
Storage : | Store at -80 centigrade after receiving vials. |
Concentration : | >50 μg/mL as determined by microplate BCA method |
Storage Buffer : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Gene Name : | Arhgdia Rho GDP dissociation inhibitor (GDI) alpha [ Mus musculus (house mouse) ] |
Official Symbol : | Arhgdia |
Synonyms : | ARHGDIA; Rho GDP dissociation inhibitor (GDI) alpha; rho GDP-dissociation inhibitor 1; rho GDI 1; Rho GDI alpha; rho-GDI alpha; Gdi-1; RhoDGI; Rho-GDI; RhoGDI-1; MGC7904; 5330430M07Rik; MGC101921 |
Gene ID : | 192662 |
mRNA Refseq : | NM_133796 |
Protein Refseq : | NP_598557 |
UniProt ID : | Q99PT1 |
Products Types
◆ Recombinant Protein | ||
ARHGDIA-424R | Recombinant Rat ARHGDIA Protein, His (Fc)-Avi-tagged | +Inquiry |
ARHGDIA-688M | Recombinant Mouse ARHGDIA Protein, His (Fc)-Avi-tagged | +Inquiry |
ARHGDIA-60C | Recombinant Cynomolgus Monkey ARHGDIA Protein, His (Fc)-Avi-tagged | +Inquiry |
ARHGDIA-5136H | Recombinant Human ARHGDIA protein, GST-tagged | +Inquiry |
ARHGDIA-768R | Recombinant Rat ARHGDIA Protein | +Inquiry |
◆ Lysates | ||
ARHGDIA-8736HCL | Recombinant Human ARHGDIA 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (9)
Ask a questionCurrent research on ARHGDIA focuses on elucidating its role in various cellular processes and disease mechanisms. Scientists are investigating its involvement in cancer progression, metastasis, and therapeutic targeting potential. Additionally, studies are exploring the molecular mechanisms of ARHGDIA regulation and its interactions with other proteins and signaling pathways.
Yes, alterations in ARHGDIA expression or mutations in the ARHGDIA gene have been linked to certain diseases. In addition to neutrophil-specific granule deficiency (SGD), mentioned earlier, dysregulation of ARHGDIA has been observed in certain cancers, such as breast cancer and colorectal cancer. Abnormal ARHGDIA expression has also been associated with blood disorders and cardiovascular diseases.
Yes, targeting ARHGDIA has been explored as a potential therapeutic strategy in different diseases. For example, in cancer, inhibitors of Rho GTPases or RhoGEFs that interact with ARHGDIA have been investigated as potential anti-cancer agents. By inhibiting the activation of Rho GTPases, these compounds aim to disrupt signaling pathways involved in cancer progression and metastasis. Additionally, gene therapy approaches to modulate ARHGDIA expression levels have been explored as potential therapeutic interventions, particularly in diseases like neutrophil-specific granule deficiency.
There is emerging evidence suggesting that ARHGDIA expression levels may have diagnostic or prognostic value in certain diseases, particularly cancer. Alterations in ARHGDIA expression have been associated with tumor grade, metastatic potential, and patient survival outcomes in some studies. However, further research and validation are required before it can be considered a reliable clinical marker.
There is limited evidence suggesting the involvement of ARHGDIA in neural development and neurological disorders. Recent studies have found that ARHGDIA is expressed in the nervous system and may play a role in neuronal migration and axon guidance. However, further research is needed to fully understand its specific contributions to neural development and its potential involvement in neurological disorders.
Yes, several animal models have been developed to study the function and roles of ARHGDIA. Knockout mouse models lacking ARHGDIA expression have been generated, allowing researchers to investigate the impact of ARHGDIA deficiency in various tissues and organs. These models have provided valuable insights into the physiological and pathological roles of ARHGDIA in different systems.
Yes, ARHGDIA interacts with several proteins and molecules. It binds to Rho GTPases, specifically to their active GTP-bound form, preventing their activation. ARHGDIA also interacts with other regulatory proteins, such as Rho guanine nucleotide exchange factors (RhoGEFs) and Rho GTPase activating proteins (RhoGAPs), to modulate Rho GTPase activity. Additionally, ARHGDIA has been reported to interact with cytoskeletal proteins and participate in the regulation of actin dynamics.
Yes, various mutations and genetic variations in the ARHGDIA gene have been identified. Some mutations can result in altered protein function, leading to diseases or developmental disorders. For example, a specific mutation in the ARHGDIA gene has been associated with a rare genetic disorder called neutrophil-specific granule deficiency (SGD), characterized by impaired neutrophil function.
The dysregulation of ARHGDIA in diseases, particularly cancer, suggests it could be a potential therapeutic target. Strategies to modulate ARHGDIA expression or activity may help regulate Rho GTPase signaling, leading to potential therapeutic benefits in cancer treatment. However, more research is needed to fully understand the therapeutic potential and feasibility of targeting ARHGDIA.
Customer Reviews (8)
Write a reviewthe ARHGDIA protein is an exceptional tool for investigating the intricate mechanisms and pathogenesis of amyloid-related diseases.
Their profound knowledge and expertise will undoubtedly help me overcome any challenges that arise, and their prompt assistance ensures a seamless progression of my research.
the exemplary technical support provided by the manufacturer adds immense value to my experience.
If needed, the availability of bulk purchase options further optimizes resource allocation, enabling me to conduct extensive experiments without compromising on quality.
I am confident that their expertise and prompt assistance can help resolve any challenges I may encounter along the way.
the ARHGDIA protein's exceptional quality, coupled with the manufacturer's outstanding technical support, ensures that it fulfills my experimental needs with utmost precision and efficacy.
Their collaboration during trial design and data analysis enhances the reliability and significance of my research findings.
Whether it's troubleshooting experimental hurdles or optimizing protocols, their dedicated team is there to guide me, ensuring smooth progress and successful outcomes.
Ask a Question for All Arhgdia Products
Required fields are marked with *
My Review for All Arhgdia Products
Required fields are marked with *
Inquiry Basket